| Year |
Citation |
Score |
| 2024 |
Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, MacConaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K. Author Correction: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Nature Medicine. PMID 38383797 DOI: 10.1038/s41591-024-02866-2 |
0.395 |
|
| 2023 |
Nardi F, Perurena N, Schade AE, Li ZH, Ngo K, Ivanova EV, Saldanha A, Li C, Gokhale PC, Hata AN, Barbie DA, Paweletz CP, Janne PA, Cichowski K. Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer. The Journal of Clinical Investigation. PMID 37384411 DOI: 10.1172/JCI167651 |
0.312 |
|
| 2023 |
Perurena N, Lock R, Davis RA, Raghavan S, Pilla NF, Ng R, Loi P, Guild CJ, Miller AL, Sicinska E, Cleary JM, Rubinson DA, Wolpin BM, Gray NS, Santagata S, ... ... Cichowski K, et al. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Reports. Medicine. 101007. PMID 37030295 DOI: 10.1016/j.xcrm.2023.101007 |
0.41 |
|
| 2023 |
Miller AL, Perurena N, Gardner A, Hinoue T, Loi P, Laird PW, Cichowski K. DAB2IP is a bifunctional tumor suppressor that regulates wildtype RAS and inflammatory cascades in KRAS mutant colon cancer. Cancer Research. PMID 36939385 DOI: 10.1158/0008-5472.CAN-22-0370 |
0.547 |
|
| 2020 |
Zhang Y, Guillermier C, De Raedt T, Cox AG, Maertens O, Yimlamai D, Lun M, Whitney A, Maas RL, Goessling W, Cichowski K, Steinhauser ML. Imaging Mass Spectrometry Reveals Tumor Metabolic Heterogeneity. Iscience. 23: 101355. PMID 32712466 DOI: 10.1016/J.Isci.2020.101355 |
0.392 |
|
| 2020 |
Guerra SL, Maertens O, Kuzmickas R, De Raedt T, Adeyemi RO, Guild CJ, Guillemette S, Redig AJ, Chambers ES, Xu M, Tiv H, Santagata S, Jänne PA, Elledge SJ, Cichowski K. A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell. PMID 32243838 DOI: 10.1016/J.Ccell.2020.03.004 |
0.403 |
|
| 2020 |
Tian T, Lofftus S, Pan Y, Stingley CA, King SL, Zhao J, Pan TY, Lock R, Marglous JW, Liu K, Widlund HR, Fuhlbrigge RC, Cichowski K, Kupper TS. IL1α antagonizes IL1β and promotes adaptive immune rejection of malignant tumors. Cancer Immunology Research. PMID 32161110 DOI: 10.1158/2326-6066.Cir-19-0552 |
0.396 |
|
| 2020 |
Kim A, Lu Y, Okuno SH, Reinke D, Maertens O, Perentesis J, Basu M, Wolters PL, De Raedt T, Chawla S, Chugh R, Van Tine BA, O'Sullivan G, Chen A, Cichowski K, et al. Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). Sarcoma. 2020: 5784876. PMID 32089640 DOI: 10.1155/2020/5784876 |
0.318 |
|
| 2020 |
Watanabe M, Kuzmickas R, Cichowski K. Abstract P1-18-27: Developing a novel combination therapy using EZH2i for HER2+ breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-18-27 |
0.316 |
|
| 2019 |
Widemann BC, Lu Y, Reinke D, Okuno SH, Meyer CF, Cote GM, Chugh R, Milhem MM, Hirbe AC, Kim A, Turpin B, Pressey JG, Dombi E, Jayaprakash N, Helman LJ, ... ... Cichowski K, et al. Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma. 2019: 7656747. PMID 31427883 DOI: 10.1155/2019/7656747 |
0.42 |
|
| 2019 |
Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, Rosenfeld JA, Cox AG, Hedgepeth J, Wucherpfennig JI, Kim AJ, Henderson JE, Gonyo P, Brandt A, Lorimer E, ... ... Cichowski K, et al. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nature Genetics. PMID 31406347 DOI: 10.1038/S41588-019-0475-Y |
0.514 |
|
| 2019 |
Haigis KM, Cichowski K, Elledge SJ. Tissue-specificity in cancer: The rule, not the exception. Science (New York, N.Y.). 363: 1150-1151. PMID 30872507 DOI: 10.1126/Science.Aaw3472 |
0.546 |
|
| 2019 |
Maertens O, Kuzmickas R, Manchester HE, Emerson CE, Gavin AG, Guild CJ, Wong TC, De Raedt T, Bowman-Colin C, Hatchi E, Garraway LA, Flaherty KT, Pathania S, Elledge SJ, Cichowski K. MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF, NRAS, and NF1 mutant melanomas. Cancer Discovery. PMID 30709805 DOI: 10.1158/2159-8290.Cd-18-0879 |
0.486 |
|
| 2018 |
Liao S, Maertens O, Cichowski K, Elledge SJ. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is. Genes & Development. PMID 30135075 DOI: 10.1101/Gad.315648.118 |
0.374 |
|
| 2018 |
Takahashi N, Chen HY, Harris IS, Stover DG, Selfors LM, Bronson RT, Deraedt T, Cichowski K, Welm AL, Mori Y, Mills GB, Brugge JS. Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell. PMID 29805077 DOI: 10.1016/J.Ccell.2018.05.001 |
0.308 |
|
| 2017 |
Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, ... ... Cichowski K, et al. Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. Cell Reports. 21: 2796-2812. PMID 29212027 DOI: 10.1016/J.Celrep.2017.11.022 |
0.376 |
|
| 2017 |
Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K. A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Research. PMID 28993414 DOI: 10.1158/0008-5472.Can-17-1789 |
0.364 |
|
| 2017 |
Malone CF, Emerson C, Ingraham R, Barbosa W, Guerra S, Yoon H, Liu LL, Michor F, Haigis M, Macleod KF, Maertens O, Cichowski K. mTOR and HDAC inhibitors converge on the TXNIP/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors. Cancer Discovery. PMID 28963352 DOI: 10.1158/2159-8290.Cd-17-0177 |
0.75 |
|
| 2017 |
Lock R, Ingraham R, Maertens O, Konicek B, Yan S, Graff J, Cichowski K. Abstract A18: Targeting the MNK kinases for the treatment of NF1-mutant cancers Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A18 |
0.581 |
|
| 2017 |
Takahashi N, Chen H, Harris I, Stover D, Bronson R, Deraedt T, Cichowski K, Welm A, Mills G, Brugge J. Abstract 5478: The TRPA1 Ca2+-permeable channel mediates a non-canonical redox adaptation in cancer cells Cancer Research. 77: 5478-5478. DOI: 10.1158/1538-7445.Am2017-5478 |
0.393 |
|
| 2017 |
Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, Rosenfeld JA, Cox AG, Hedgepeth J, Wücherpfennig J, Kim AJ, Henderson JE, Gonyo P, Brandt A, Lorimer E, ... ... Cichowski K, et al. Abstract 4272: Mutations inRABL3alter RAS prenylation and are associated with hereditary pancreatic cancer Epidemiology. 77: 4272-4272. DOI: 10.1158/1538-7445.Am2017-4272 |
0.462 |
|
| 2016 |
Olsen SN, Wronski A, Castaño Z, Dake B, Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, Loda M, Welm A, Partridge AH, McAllister SS, Kuperwasser C, ... Cichowski K, et al. Loss of RasGAP Tumor Suppressors Underlie the Aggressive Nature of Luminal B Breast Cancers. Cancer Discovery. PMID 27974415 DOI: 10.1158/2159-8290.Cd-16-0520 |
0.523 |
|
| 2016 |
Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, ... ... Cichowski K, et al. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discovery. PMID 27312177 DOI: 10.1158/2159-8290.Cd-16-0164 |
0.667 |
|
| 2016 |
Lock R, Ingraham R, Maertens O, Miller AL, Weledji N, Legius E, Konicek BM, Yan SB, Graff JR, Cichowski K. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. The Journal of Clinical Investigation. PMID 27159396 DOI: 10.1172/Jci85183 |
0.634 |
|
| 2016 |
Widemann BC, Meyer CF, Cote GM, Chugh R, Milhem MM, Van Tine BA, Kim A, Turpin B, Dombi E, Jayaprakash N, Okuno SH, Helman LJ, Onwudiwe N, Steinberg SM, Reinke DK, ... Cichowski K, et al. SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). Journal of Clinical Oncology. 34: 11053-11053. DOI: 10.1200/Jco.2016.34.15_Suppl.11053 |
0.49 |
|
| 2015 |
Lock R, Cichowski K. Loss of negative regulators amplifies RAS signaling. Nature Genetics. 47: 426-7. PMID 25916896 DOI: 10.1038/Ng.3299 |
0.559 |
|
| 2015 |
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 160: 977-89. PMID 25723171 DOI: 10.1016/J.Cell.2015.01.042 |
0.319 |
|
| 2014 |
De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, Clapp W, Bradner J, Vidaud M, Upadhyaya M, Legius E, ... Cichowski K, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 514: 247-51. PMID 25119042 DOI: 10.1038/Nature13561 |
0.58 |
|
| 2014 |
Malone CF, Fromm JA, Maertens O, DeRaedt T, Ingraham R, Cichowski K. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discovery. 4: 1062-73. PMID 24913553 DOI: 10.1158/2159-8290.Cd-14-0159 |
0.577 |
|
| 2014 |
Maertens O, Cichowski K. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer Advances in Biological Regulation. 55: 1-14. PMID 24814062 DOI: 10.1016/J.Jbior.2014.04.002 |
0.54 |
|
| 2014 |
Maertens O, Cichowski K. Paths of resistance to EGFR inhibitors: is NF enough? Cancer Discovery. 4: 519-521. PMID 24795011 DOI: 10.1158/2159-8290.Cd-14-0286 |
0.368 |
|
| 2014 |
Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, et al. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. American Journal of Medical Genetics. Part A. 164: 563-78. PMID 24443315 DOI: 10.1002/Ajmg.A.36312 |
0.521 |
|
| 2014 |
Kim A, Reinke DK, Cichowski K, Perentesis JP, Wolters P, Martin S, Dombi E, Steinberg SM, Widemann BC. SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps10603 |
0.394 |
|
| 2014 |
Raedt TD, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Mautner V, Kehrer-Sawatski H, Clapp W, Bradner J, Upadhyaya M, Vidaud M, Legius E, Cichowski K. Abstract LB-79: PRC2 loss amplifies Ras-driven transcription and sensitizes cancers to bromodomain inhibitor-based combination therapies Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-79 |
0.449 |
|
| 2013 |
McLaughlin SK, Olsen SN, Dake B, De Raedt T, Lim E, Bronson RT, Beroukhim R, Polyak K, Brown M, Kuperwasser C, Cichowski K. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell. 24: 365-78. PMID 24029233 DOI: 10.1016/J.Ccr.2013.08.004 |
0.559 |
|
| 2013 |
Hollstein PE, Cichowski K. Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discovery. 3: 880-93. PMID 23661552 DOI: 10.1158/2159-8290.Cd-13-0146 |
0.84 |
|
| 2013 |
Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discovery. 3: 338-49. PMID 23171796 DOI: 10.1158/2159-8290.Cd-12-0313 |
0.821 |
|
| 2013 |
Raedt TD, Beert E, Pasmant E, Bradner JE, Wolkenstein P, Legius E, Cichowski K. Abstract PR15: SUZ12: A novel tumor suppressor and potential biomarker for efficacy of BRD4 inhibition Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-Pr15 |
0.554 |
|
| 2013 |
Maertens O, Johnson B, Hollstein P, Frederick D, Cooper Z, Messiaen L, Bronson R, McMahon M, Granter S, Flaherty K, Wargo J, Marais R, Cichowski K. Abstract 5201: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Research. 73: 5201-5201. DOI: 10.1158/1538-7445.Am2013-5201 |
0.823 |
|
| 2013 |
Cichowski K. Abstract PL04-01: Developing therapies for Ras driven cancers. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pl04-01 |
0.486 |
|
| 2012 |
McClatchey AI, Cichowski K. SPRED proteins provide a NF-ty link to Ras suppression. Genes & Development. 26: 1515-9. PMID 22802525 DOI: 10.1101/Gad.197434.112 |
0.524 |
|
| 2012 |
Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Evans DG, Giancotti F, Hanemann CO, Ingram D, Lloyd AC, Mayes DA, Messiaen L, Morrison H, North K, Packer R, et al. Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. Acta Neuropathologica. 123: 369-80. PMID 22083253 DOI: 10.1007/S00401-011-0905-0 |
0.497 |
|
| 2011 |
Beert E, Brems H, Daniëls B, De Wever I, Van Calenbergh F, Schoenaers J, Debiec-Rychter M, Gevaert O, De Raedt T, Van Den Bruel A, de Ravel T, Cichowski K, Kluwe L, Mautner V, Sciot R, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes, Chromosomes & Cancer. 50: 1021-32. PMID 21987445 DOI: 10.1002/Gcc.20921 |
0.462 |
|
| 2011 |
De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, ... ... Cichowski K, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 20: 400-13. PMID 21907929 DOI: 10.1016/J.Ccr.2011.08.014 |
0.724 |
|
| 2011 |
Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, et al. Back to the future: proceedings from the 2010 NF Conference. American Journal of Medical Genetics. Part A. 155: 307-21. PMID 21271647 DOI: 10.1002/Ajmg.A.33804 |
0.49 |
|
| 2010 |
Cichowski K, Jänne PA. Drug discovery: inhibitors that activate. Nature. 464: 358-359. PMID 20237552 DOI: 10.1038/464358A |
0.343 |
|
| 2010 |
Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nature Medicine. 16: 286-94. PMID 20154697 DOI: 10.1038/Nm.2100 |
0.528 |
|
| 2009 |
McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, ... ... Cichowski K, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 16: 44-54. PMID 19573811 DOI: 10.1016/J.Ccr.2009.05.009 |
0.713 |
|
| 2008 |
Cichowski K, Hahn WC. Unexpected Pieces to the Senescence Puzzle Cell. 133: 958-961. PMID 18555773 DOI: 10.1016/J.Cell.2008.05.027 |
0.32 |
|
| 2008 |
Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene. 27: 2801-9. PMID 18193093 DOI: 10.1038/Sj.Onc.1210950 |
0.496 |
|
| 2008 |
Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K. TORC1 is essential for NF1-associated malignancies. Current Biology : Cb. 18: 56-62. PMID 18164202 DOI: 10.1016/J.Cub.2007.11.066 |
0.795 |
|
| 2006 |
Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell. 10: 459-72. PMID 17157787 DOI: 10.1016/J.Ccr.2006.10.003 |
0.68 |
|
| 2005 |
Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proceedings of the National Academy of Sciences of the United States of America. 102: 8573-8. PMID 15937108 DOI: 10.1073/Pnas.0503224102 |
0.82 |
|
| 2005 |
Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America. 102: 3788-93. PMID 15731348 DOI: 10.1073/Pnas.0409773102 |
0.32 |
|
| 2004 |
Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Research. 64: 3718-24. PMID 15150133 DOI: 10.1158/0008-5472.Can-03-4079 |
0.428 |
|
| 2003 |
Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes & Development. 17: 449-54. PMID 12600938 DOI: 10.1101/Gad.1054703 |
0.764 |
|
| 2001 |
Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 104: 593-604. PMID 11239415 DOI: 10.1016/S0092-8674(01)00245-8 |
0.682 |
|
| 1999 |
Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science (New York, N.Y.). 286: 2172-6. PMID 10591652 DOI: 10.1126/Science.286.5447.2172 |
0.729 |
|
| 1997 |
Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, Bronson RT, Umanoff H, Edelmann W, Kucherlapati R, Jacks T. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes & Development. 11: 2468-81. PMID 9334313 DOI: 10.1101/Gad.11.19.2468 |
0.792 |
|
| 1997 |
Cichowski K, Shih TS, Jacks T. Nf1 gene targeting: toward models and mechanisms. Seminars in Cancer Biology. 7: 291-8. PMID 9110406 DOI: 10.1006/Scbi.1996.0037 |
0.703 |
|
| Show low-probability matches. |